Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2022 | The role of APOBECs in myeloma & incorporating APOBECs in current risk stratification models

Florian Kuchenbauer • 27 Aug 2022
IMS 2022
Multiple Myeloma

Florian Kuchenbauer, MD, PhD, BC Cancer, Vancouver, Canada, comments on the role of APOBECs in multiple myeloma, highlighting how the inclusion of APOBECs into current risk stratification models can help better stratify patients with multiple myeloma, and discussing the impact of APOBECs in inflammation. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals